NCT00102453View on ClinicalTrials.gov

Pentoxifylline in Duchenne Muscular Dystrophy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

July 31, 2006

Study Completion Date

May 31, 2007

Conditions
Muscular Dystrophy, Duchenne
Interventions
DRUG

Pentoxifylline

Pentoxifylline dosing: 20mg/Kg/day in a 20 mg/mL solution. Maximum dose of 1200mg/day. Dosing split into two equal parts taken morning and night with food.

Trial Locations (5)

15213

Children's Hospital of Pittsburgh, Pittsburgh

20010

Children's National Medical Center, Washington D.C.

55905

Mayo Clinic, Rochester

63110

Washington University at St. Louis, St Louis

Unknown

Texas Scottish Rite Hospital, Dallas

All Listed Sponsors
lead

Cooperative International Neuromuscular Research Group

NETWORK

NCT00102453 - Pentoxifylline in Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter